|  |
| --- |
| March 27, 2018**Contact person specialized press****Dr. Torsten Stojanik**Communications & IntegrationPhone +49 201 177-4094Mobile +49-151 1510 1277torsten.stojanik@evonik.com |
|  |

**Evonik Performance
Materials GmbH**

Rellinghauser Straße 1-11

45128 Essen

Germany

Phone +49 201 177-01

Fax +49 201 177-3475

[www.evonik.com](http://www.evonik.com)

**Supervisory Board**

Dr. Harald Schwager, Chairman

**Managing Directors**

Johann-Caspar Gammelin, Chairman

Dr. Michael Pack

Magdalena Wagner

Rainer Wobbe

Registered Office Essen

Register Court

City Local Court Essen

Commercial Registry B 25779

**Evonik joint venture expands capacity for TAA derivatives in China**

* 50 percent capacity increase
* Evonik to solidify its leading position in TAA derivatives
* Strong growth potential in the future

Evonik Tianda (Liaoyang) Chemical Additive Co., Ltd. (ETL) has increased its production capacity for triacetonamine (TAA) derivatives in Liaoyang by 50 percent. With the expansion, the joint venture of Evonik China and the Chinese NEPC (Northeast No.1 Electric Power Construction CO., Ltd.) is responding to continuous growth in market demand.

TAA derivatives are essential precursors for the manufacture of hindered amine light stabilizers (HALS). The additives are used in low concentrations to protect and stabilize polymers against decomposition caused by light, oxygen and heat and can therefore increase the life expectancy of plastic materials up to ten times. They are found in many products of the automotive and construction industry as well as in the manufacture of agricultural films.

“With our new production capacities, we can support the growth of our customers and serve global markets even more effectively,” says Zhong Yao, managing director of ETL. The construction work for the expansion began in 2017 and was successfully completed in March 2018.

“We have been a successful player in the global TAA derivatives market for over 30 years,” says Thomas Wildt, head of the Agrochemicals & Polymer Additives Business Line. “The investment in the Liaoyang site further solidifies our leading position in TAA derivatives and consistently follows our strategy of intelligently shaping our ChemicalBusiness.” Evonik expects continuous growth in the market segment in upcoming years.

Evonik is a leading global manufacturer of TAA and TAA derivatives. The company offers a broad range of TAA derivatives (e.g. hexamethylene-bis-triacetone diamine, triacetone diamine) and custom-tailored molecules on the basis of TAA. In addition to the facility in Liaoyang, Evonik maintains production capacities at the Marl Chemical Park.

**About Evonik**

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.

**About Performance Materials**

The Performance Materials Segment is managed by Evonik Performance Materials GmbH. The segment focuses its global activities on developing and manufacturing polymer materials and intermediates, especially for use in agriculture and in the rubber and plastics industry. In 2017, the segment’s roughly 4,400 employees generated sales about €3.7 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.